06/30/2026

Computerized Systems Validation in Bioanalysis: Regulatory Requirements and How It Works in Practice

SHARE

Ready to discuss your bioanalytical study requirements?

Anapharm Bioanalytics provides bioanalytical support to drug development programmes across both small and large molecule, from early discovery phase, GLP tox studies through Phase I-III.
Speak with a bioanalytical specialist today.

Author: Natalia Caparrós – Quality Assurance Unit Director & Lara Martínez – CSV Technician at Anapharm | Last updated: June 2026

Introduction

Computerized System Validation (CSV) is a fundamental requirement in GLP & GCP-regulated environments. As laboratories increasingly rely on computerized systems to generate, process, store, and report data, it is essential to ensure that these systems are fit for their intended use and operate consistently and reliably. Beyond regulatory compliance, sponsors also expect laboratories to demonstrate that computerized systems are properly validated, ensuring the integrity, reliability, and traceability of study data.
In this blog post, we will take a closer look at the importance of CSV in a GLP & GCP environment and explore some of the key computerized systems that play a critical role in supporting our laboratory operations and ensuring data quality.

Table of Contents

1. What is computerized system validation?
2. Which regulatory frameworks govern CSV?
3. Which systems require validation at a bioanalytical CRO?
4. What is often underestimated about CSV?
5. Cybersecurity as part of CSV.
6. Why does CSV matter in bioanalysis?
7. What are the benefits of a robust CSV programme?

What is computerized system validation?

Computerized system validation is the documented, risk-based process of demonstrating that a computer system consistently performs its intended function and produces data that is accurate, reliable, and tamper-evident throughout its entire lifecycle [1]. The objective is to provide documented assurance that the system, as configured and used in the laboratory, produces defensible records that support regulatory compliance and scientific integrity. This applies to a wide range of computerized systems, including those used to control the acquisition and processing of analytical data, as well as systems supporting the quality management system.
Computerized System Validation typically comprises three main stages: Installation Qualification (IQ), which verifies that the system is installed correctly; Operational Qualification (OQ), which confirms that the system functions as intended; and Performance Qualification (PQ), which demonstrates that the system, when operated according to approved SOPs by trained users, fulfills its intended use in the laboratory environment.

Which regulatory frameworks govern CSV?

In the pharmaceutical industry, computerized system validation is subject to extensive regulatory requirements across GMP, GCP, and GLP. Our laboratory is primarily focused on ensuring compliance with the following GLP & GCP applicable standards:
• EMA guideline on computerized systems and electronic data in clinical trials [2]: sets out how to ensure that digital tools and data are properly validated, securely managed, and reliably maintained to protect data integrity and regulatory compliance throughout clinical research.
• OECD Advisory Document No. 17 [3]: explains how Good Laboratory Practice (GLP) principles should be applied to computerized systems to ensure their reliability, integrity, traceability, and regulatory compliance in non-clinical laboratory studies.
• FDA 21 CFR Part 11 [4]: the US federal regulation for electronic records and electronic signatures. It requires that computerized systems are validated to ensure accuracy, reliability, and consistent intended performance, and that they maintain secure, time-stamped audit trails with controlled access [5].
• GAMP 5 [5]: not a regulation, but the industry-standard implementation framework published by the International Society for Pharmaceutical Engineering (ISPE). It classifies software by type and scales validation effort to each system's potential risk to data quality and patient safety, and is used globally to implement the requirements of 21 CFR Part 11 and Annex 11.

Which systems require validation at a bioanalytical CRO?

Any computerized system that affects how regulated data is captured, processed, stored, or reported requires validation, with effort scaled to the system's complexity and risk. At Anapharm, sponsors benefit from a validated portfolio spanning commercial platforms and internally developed systems purpose-built for our environment, providing end-to-end traceability, automated reporting, and full alignment between our systems and the studies we run.

Below are some representative examples that illustrate the broad range of systems used in our laboratory.

LIMS (Laboratory Information Management System) GAMP 4 & 5

Tracks every sample from receipt to disposal; manages instrument calibration and maintenance records; oversees the full study cycle for Large Molecule Bioanalysis including sequence creation and results evaluation.

Analyst GAMP 4

Generates raw chromatographic data for LC-MS/MS analyses in Small Molecule Bioanalysis.

SCIEX OS GAMP 4

Generates raw chromatographic data for Anapharm's newest LC-MS/MS platforms, expanding instrument control and reporting capabilities (under validation).

MSD (Methodical Mind) GAMP 3

Electrochemiluminescence plate reader – Data processing software in Large Molecule Bioanalysis.

SciLife GAMP 3

Records and manages quality events: deviations (non-conformances identified during studies or audits), Corrective and Preventive Actions (CAPAs), and controlled documents including Standard Operating Procedures (SOPs).

SecureDocs GAMP 3

Shares regulated documents securely with Sponsors and auditors.

Octopus GAMP 5

Internally developed web-based system. It enables tracking the use of automated pipettes, generating sample management reports (including inventories, incidents, and movement history), and automatically producing study report tables for both small and large molecule bioanalysis by directly extracting data from LIMS and Analyst/SciexOS systems.

Butterfly GAMP 5

Internally developed system managing the Master Schedule (LEP) and study archive.

What is often underestimated about CSV?

A common misconception is that CSV is complete once the software has been installed and tested. According to the applicable regulations, validation must also address how users interact with the system and how laboratory processes are designed around it. A system can perform exactly as designed and still produce compliance gaps if these organizational and procedural requirements are not met.
This is why at Anapharm we perform independent validation for every system, including those delivered with vendor qualification documentation. This ensures that regulatory requirements are met for our actual processes, configurations, and workflows, resulting in better alignment with internal processes and improved data integrity for every study we run.
In addition, it is essential to ensure adequate resourcing in terms of time and personnel not only for the initial validation of computerized systems, but also for maintaining their validated state through effective incident management, change control processes, and periodic reviews during all cycle lifecycle.

Cybersecurity as part of CSV

The IT infrastructure and network environment supporting the bioanalytical laboratory are considered computerized systems within the scope of CSV, as it is essential for the operation, security, availability, and integrity of GxP-relevant data and applications.
It has been appropriately validated to demonstrate fitness for their intended use and are managed throughout their lifecycle following established procedures. Ongoing control is maintained through formal Incident Management and Change Control processes, ensuring that any issues, modifications, or enhancements are assessed, documented, approved, and implemented in a controlled manner.
[AE6.1]Recognizing the increasing importance of cybersecurity in maintaining data integrity, system availability, and regulatory compliance [6], an external cybersecurity audit has been performed. It provided an objective evaluation of the organization's security posture, identifying potential vulnerabilities and verifying the effectiveness of implemented technical and organizational controls. The results support the continued protection, reliability, and integrity of computerized systems and the GxP-relevant data they process.

Why does CSV matter in bioanalysis?

Bioanalytical data generated at a CRO supports regulatory submissions at every stage of drug development.
OECD Advisory Document No. 17 for GLP studies require computerized systems to be appropriately validated, fit for their intended use, and controlled throughout their lifecycle through robust governance processes, ensuring data integrity, reliability, traceability, and regulatory compliance [3]. The EMA's 2023 Guideline on Computerized Systems and Electronic Data in Clinical Trials address the same requirements to sponsors [2].
As a result, deficiencies in computerized system validation can put the reliability and regulatory defensibility of a study’s data at risk. Selecting a bioanalytical CRO means selecting that CRO's quality system. Sponsors who rely on a CRO with a robust, audited CSV programme protect the regulatory defensibility of their own data.

What are the benefits of a robust CSV programme?

• Improved data quality. Systems validated for a specific environment produce reliable, reproducible outputs with documented controls at every step.
• Ensured data integrity. Audit trails, controlled access, and tamper-evident records in validated systems satisfy the ALCOA++ data integrity principles required by FDA 21 CFR Part 11, GLP & GCP [2,3,4].
• Reduction of manual and repetitive tasks. Validated systems automate error-prone processes such as data extraction and report table generation, reducing manual workload and the risk of transcription errors.
• Increased efficiency and time savings. Automated, validated workflows reduce study report turnaround times and free staff for higher-value analytical work.
• Optimisation of internal workflows. Validation aligns systems with laboratory-specific processes, eliminating redundant steps and improving consistency of outputs across analysts and study phases.

References

[1] Raja JR, Kella A, Narayanasamy D. The Essential Guide to Computer System Validation in the Pharmaceutical Industry. Cureus. 2024;16(8):e67555. doi:10.7759/cureus.67555. https://pmc.ncbi.nlm.nih.gov/articles/PMC11416705/
[2] European Medicines Agency. Guideline on Computerised Systems and Electronic Data in Clinical Trials. EMA/INS/GCP/112288/2023. Effective September 2023. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf
[3] Organisation for Economic Co-operation and Development (OECD). Advisory Document No. 17: The Application of GLP Principles to Computerised Systems. Series on Principles of Good Laboratory Practice and Compliance Monitoring. 2016, reissued 2022. https://one.oecd.org/document/env/jm/mono(2016)13/en/pdf
[4] U.S. Food and Drug Administration. 21 CFR Part 11: Electronic Records; Electronic Signatures. Code of Federal Regulations, Title 21, Chapter I, Subchapter A. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
[5] International Society for Pharmaceutical Engineering (ISPE). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. 2nd ed. 2022. https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition
[6] OECD Position Paper No. 25: Good Laboratory Practice and IT Security. December 2024. https://www.oecd.org/en/topics/sub-issues/testing-of-chemicals/good-laboratory-practice-and-compliance-monitoring.html